The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

Hansa Biopharma AB, "Hansa" or the "Company" , today announced its interim report for January-March 2025. Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered ...

Neurology experts from UCSF Health presented new clinical research findings and cutting-edge treatment strategies and received distinguished awards recognition at the American Academy of Neurology’s ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

Alector has announced the completion of enrollment for its Phase II clinical trial, PROGRESS-AD, evaluating the safety and ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

全身型重症肌无力 (gMG) 是一种罕见的慢性自身免疫性神经肌肉疾病 [1] ，给患者的日常生活带来了巨大的负担。常规药物包括胆碱酯酶抑制剂、糖皮质激素和非激素类免疫抑制剂，但是常规治疗疗效欠佳，患者负担仍重，并且伴随诸多不良反应 [2,3] 。

Argenx (ARGX) stock rises as the FDA approves Vyvgart Hytrulo developed with Halozyme (HALO) for self-injection, the drug's ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

Myasthenia gravis is a rare neuromuscular disorder caused by the production of pathogenic autoantibodies against neuromuscular junction components. About 80-85% of gMG patients have antibodies against ...